Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Abstract The Clinical Practice Manual for Hepatocellular Carcinoma was published based
on evidence confirmed by the Evidence-based Clinical Practice Guidelines for …

PURPOSE In a previous phase II trial, hepatic arterial infusion chemotherapy (HAIC) with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) yielded higher treatment …

Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment
of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as …

Background The synergy between locoregional therapies and immune checkpoint inhibitors
has not been investigated as conversion therapy for unresectable hepatocellular carcinoma …

Liver cancer is the fourth most prevalent and the second most lethal cancer in China.
Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma …

Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …

Introduction: Transarterial chemoembolization (TACE) is the standard treatment for
unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after …

Introduction: Several clinical trials comparing the efficacy and safety of transarterial
chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no …

Atezolizumab plus bevacizumab (Atezo/Bev) followed by curative conversion (ABC
conversion) therapy is very effective in the treatment of unresectable, transarterial …